Expression of Bim, Noxa, and Puma in non-small cell lung cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Sakakibara Konishi, Jun ^a   Oizumi, Satoshi ^a   Kikuchi, Junko ^a   Kikuchi, Eiki ^a   Mizugaki, Hidenori ^a   Kinoshita, Ichiro ^b   Dosaka Akita, Hirotoshi ^b   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN NOXA; PUMA PROTEIN;

ADENOSQUAMOUS CARCINOMA; AGED; ARTICLE; BINDING SITE; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN BINDING; PROTEIN EXPRESSION; SMOKING HABIT; TUMOR DIFFERENTIATION;

AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN E; FEMALE; GENE EXPRESSION; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS;

EID: 84863688765     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-286     Document Type: Article

References (38)

1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med 2010, 362:2380-2388. 10.1056/NEJMoa0909530, 20573926.
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550. 10.1056/NEJMoa061884, 17167137.
3. Hengatner MO. The biochemistry of apoptosis. Nature 2000, 407:770-776. 10.1038/35037710, 11048727.
4. Cory S, Huang DC, Adamas JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607. 10.1038/sj.onc.1207102, 14634621.
5. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337. 10.1038/sj.onc.1210220, 2930981, 17322918.
6. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004, 1644:83-94. 10.1016/j.bbamcr.2003.08.012, 14996493.
7. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, et al. Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak. Science 2007, 315:856-859. 10.1126/science.1133289, 17289999.
8. Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, Letai A. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 2007, 67:11867-11875. 10.1158/0008-5472.CAN-07-1961, 18089817.
9. Urbich C, Knau A, Fichtlscherer S, Walter DH, Brühl T, Potente M, Hofmann WK, de Vos S, Zeiher AM, Dimmeler S. FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells. FASEB J 2005, 19:974-976.
10. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058. 10.1126/science.288.5468.1053, 10807576.
11. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001, 7:683-694. 10.1016/S1097-2765(01)00214-3, 11463392.
12. Michalak EM, Vandenberg CJ, Delbridge AR, Wu L, Scott CL, Adams JM, Strasser A. Apoptosis-promoted tumorigenesis: gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death. Genes Dev 2010, 24:1608-1613. 10.1101/gad.1940110, 2912558, 20679396.
13. Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 2009, 12:3173-3180.
14. Sinicrope FA, Rego RL, Okumura K, Foster NR, O'Connell MJ, Sargent DJ, Windschitl HE. Prognostic impact of Bim, Puma, and Noxa expression in human colon carcinoma. Clin Cancer Res 2008, 14:5810-5818. 10.1158/1078-0432.CCR-07-5202, 2948480, 18794091.
15. Smith L, Berrieman HK, O'Kane SL, Campbell A, Maraveyas A, Cawkwell L. Immunohistochemical detection of apoptotic markers in gastric cancer. Oncol Res 2006, 15:441-444.
16. Zantl N, Weirich G, Zall H, Seiffert BM, Fischer SF, Kirschnek S, Hartmann C, Fritsch RM, Gillissen B, Daniel PT, et al. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 2007, 26:7038-7048. 10.1038/sj.onc.1210510, 17486061.
17. Berrieman HK, Smith L, O'Kane SL, Campbell A, Lind MJ, Cawkwell L. The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes. Cancer 2005, 103:1415-1419. 10.1002/cncr.20907, 15700269.
18. Borner MM, Brousset P, Pfanner-Meyer B, Bacci M, Vonlanthen S, Hotz MA, Altermatt HJ, Schalifer D, Reed JC, Betticher DC. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer 1999, 79:952-958. 10.1038/sj.bjc.6690152, 2362678, 10070896.
19. Beahrs O, Henson DE, Hutter RVP, Kennedy BJ E. American Joint Committee on Cancer. Lung. In: AJCC Manual for Staging of Cancer. Philadelphia; Lippincott 1992: 115-122, American Joint Committee on Cancer. Lung. In:.
20. Doaka-Akita H, Katabami M, Hommura H, Fujioka Y, Katoh H, Kawakami Y. Bcl-2 expression in non-small cell lung cancers: Higher frequency of expression in squamous cell carcinomas with earlier pT status. Oncology 1999, 56:259-264. 10.1159/000011974, 10202283.
21. Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci. 2003, 94:394-399. 10.1111/j.1349-7006.2003.tb01453.x, 12824911.
22. High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 2010, 77:483-494. 10.1124/mol.109.060780, 20038611.
23. Konishi J, Yi F, Chen X, Vo H, Carbone DP, Dang TP. Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene 2010, 29:589-596. 10.1038/onc.2009.366, 2813325, 19881544.
24. Hommura F, Dosaka-Akita H, Mishina T, Nishi M, Kojima T, Hiroumi H, Ogura S, Shimizu M, Katoh H, Kawakami Y. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 2000, 6:4073-4081.
25. Mishina T, Dosaka-Akita H, Hommura F, Nishi M, Kojima T, Ogura S, Shimizu M, Katoh H, Kawakami Y. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin Cancer Res 2000, 6:11-16.
26. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551. 10.1200/JCO.2007.15.0375, 18506025.
27. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 2007, 4:e294. 10.1371/journal.pmed.0040294, 2001209, 17927446.
28. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007, 4:1669-1679. 2043012, 17973572.
29. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007, 4:1681-1689. 2043013, 17973573.
30. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681. 10.1038/nature03579, 15902208.
31. Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008, 1:S149-157.
32. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008, 68:3421-3428. 10.1158/0008-5472.CAN-07-5836, 18451170.
33. Wesarg E, Hoffarth S, Wiewrodt R, Kröll M, Biesterfeld S, Huber C, Schuler M. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 2007, 121:2387-2394. 10.1002/ijc.22977, 17688235.
34. Kim KW, Moretti L, Mitchell LR, Jung DK, Lu B. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model. Clin Cancer Res 2009, 15:6096-6105. 10.1158/1078-0432.CCR-09-0589, 2756330, 19773376.
35. Jansson AK, Emterling AM, Arbman G, Sun XF. Noxa in cololectal cancer: a study on DNA, mRNA and protein expression. Oncogene 2003, 22:4675-4678. 10.1038/sj.onc.1206655, 12879012.
36. Jansson A, Arbman G, Sun XF. mRNA and protein expression of PUMA in sporadic cololectal cancer. Oncol Rep 2004, 12:1245-1249.
37. Kumamoto H, Ooya K. Immunohistochemical detection of BH3-only proteins in ameloblastic tumors. Oral Dis 2008, 14:550-555. 10.1111/j.1601-0825.2007.01417.x, 18826384.
38. O'Kane SL, Pound RJ, Campbell A, Chaudhuri N, Lind MJ, Cawkwell L. Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol 2006, 45:449-453. 10.1080/02841860500468927, 16760181.